Eric Easom's most recent trade in AN2 Therapeutics Inc was a trade of 10,000 Common Stock done at an average price of $1.1 . Disclosure was reported to the exchange on June 2, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| AN2 Therapeutics Inc | Eric Easom | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 1.07 per share. | 02 Jun 2025 | 10,000 | 256,380 | - | 1.1 | 10,665 | Common Stock |
| AN2 Therapeutics Inc | Eric Easom | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2025 | 290,500 | 290,500 | - | - | Stock Option (right to buy) | |
| AN2 Therapeutics Inc | Eric Easom | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2025 | 145,250 | 246,380 | - | 0 | Common Stock | |
| AN2 Therapeutics Inc | Eric Easom | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 1.00 per share. | 18 Nov 2024 | 50,000 | 1,065,766 | - | 1.0 | 49,970 | Common Stock |
| AN2 Therapeutics Inc | Eric Easom | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2024 | 198,000 | 198,000 | - | - | Stock Option (right to buy) | |
| AN2 Therapeutics Inc | Eric Easom | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2024 | 99,000 | 101,130 | - | 0 | Common Stock | |
| AN2 Therapeutics Inc | Eric Easom | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2024 | 99,000 | 101,130 | - | 0 | Common Stock | |
| AN2 Therapeutics Inc | Eric Easom | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 20.09 per share. | 02 Jan 2024 | 2,777 | 2,130 | - | 20.1 | 55,802 | Common Stock |
| AN2 Therapeutics Inc | Eric Easom | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 5.38 per share. | 15 May 2023 | 10,000 | 1,015,766 | - | 5.4 | 53,770 | Common Stock |
| AN2 Therapeutics Inc | Eric Easom | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 267,650 | 267,650 | - | - | Stock Option (right to buy) | |
| AN2 Therapeutics Inc | Eric Easom | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 15.32 per share. | 10 Nov 2022 | 4,413 | 4,930 | - | 15.3 | 67,628 | Common Stock |
| AN2 Therapeutics Inc | Eric Easom | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 15.04 per share. | 10 Nov 2022 | 23 | 4,907 | - | 15.0 | 346 | Common Stock |
| AN2 Therapeutics Inc | Eric Easom | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 15.61 per share. | 08 Nov 2022 | 10,111 | 4,907 | - | 15.6 | 157,847 | Common Stock |
| AN2 Therapeutics Inc | Eric Easom | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 15.41 per share. | 08 Nov 2022 | 5,800 | 16,273 | - | 15.4 | 89,388 | Common Stock |
| AN2 Therapeutics Inc | Eric Easom | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 16.38 per share. | 08 Nov 2022 | 1,255 | 15,018 | - | 16.4 | 20,559 | Common Stock |
| AN2 Therapeutics Inc | Eric Easom | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 15.67 per share. | 03 Nov 2022 | 11,082 | 29,021 | - | 15.7 | 173,683 | Common Stock |
| AN2 Therapeutics Inc | Eric Easom | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 15.90 per share. | 03 Nov 2022 | 10,167 | 6,943 | - | 15.9 | 161,705 | Common Stock |
| AN2 Therapeutics Inc | Eric Easom | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 15.80 per share. | 03 Nov 2022 | 8,828 | 17,110 | - | 15.8 | 139,474 | Common Stock |
| AN2 Therapeutics Inc | Eric Easom | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 16.02 per share. | 03 Nov 2022 | 3,083 | 25,938 | - | 16.0 | 49,376 | Common Stock |
| AN2 Therapeutics Inc | Eric Easom | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 16.72 per share. | 03 Nov 2022 | 2,036 | 4,907 | - | 16.7 | 34,036 | Common Stock |
| AN2 Therapeutics Inc | Eric Easom | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 15.39 per share. | 31 Oct 2022 | 2,688 | 6,451 | - | 15.4 | 41,363 | Common Stock |
| AN2 Therapeutics Inc | Eric Easom | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 15.07 per share. | 31 Oct 2022 | 1,544 | 4,907 | - | 15.1 | 23,263 | Common Stock |
| AN2 Therapeutics Inc | Eric Easom | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 15.69 per share. | 24 Oct 2022 | 4,272 | 7,119 | - | 15.7 | 67,020 | Common Stock |
| AN2 Therapeutics Inc | Eric Easom | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 16.17 per share. | 24 Oct 2022 | 2,866 | 11,391 | - | 16.2 | 46,344 | Common Stock |
| AN2 Therapeutics Inc | Eric Easom | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 15.10 per share. | 24 Oct 2022 | 1,678 | 4,907 | - | 15.1 | 25,342 | Common Stock |
| AN2 Therapeutics Inc | Eric Easom | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 16.20 per share. | 24 Oct 2022 | 534 | 6,585 | - | 16.2 | 8,652 | Common Stock |
| AN2 Therapeutics Inc | Eric Easom | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 16.29 per share. | 20 Oct 2022 | 11,601 | 7,257 | - | 16.3 | 189,008 | Common Stock |
| AN2 Therapeutics Inc | Eric Easom | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 16.68 per share. | 20 Oct 2022 | 7,262 | 18,889 | - | 16.7 | 121,140 | Common Stock |
| AN2 Therapeutics Inc | Eric Easom | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 16.69 per share. | 20 Oct 2022 | 2,350 | 4,907 | - | 16.7 | 39,232 | Common Stock |
| AN2 Therapeutics Inc | Eric Easom | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 17.16 per share. | 20 Oct 2022 | 31 | 18,858 | - | 17.2 | 532 | Common Stock |
| AN2 Therapeutics Inc | Eric Easom | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 May 2022 | 225,000 | 225,000 | - | - | Stock Option (right to buy) | |
| AN2 Therapeutics Inc | Eric Easom | Director, Chief Executive Officer | 29 Mar 2022 | 4,907 | 0 | - | - | Series A Convertible Preferred Stock | ||
| AN2 Therapeutics Inc | Eric Easom | Director, Chief Executive Officer | 29 Mar 2022 | 4,907 | 4,907 | - | - | Common Stock |